{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:41:50Z","timestamp":1792420910506,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,19]]},"DOI":"10.7759\/cureus.118166","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:58:32Z","timestamp":1792418312000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Response to Upadacitinib in Treatment-Experienced Patients With Atopic Dermatitis: A Case Series From Latin America"],"prefix":"10.7759","author":[{"given":"Ana B","family":"Crocker Sandoval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yocelin N","family":"Lozano Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana G","family":"Perez-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan O","family":"Muro-Davalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000045239","article-title":"The efficacy and safety of upadacitinib in atopic dermatitis: a systematic review and meta-analysis","volume":"104","author":"Molla A","year":"2025","unstructured":"Molla A, Alahmadi M, Alghamdi S, et al.. The efficacy and safety of upadacitinib in atopic dermatitis: a systematic review and meta-analysis. Medicine (Baltimore). 2025, 104:e45239. 10.1097\/MD.0000000000045239","journal-title":"Medicine (Baltimore)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky E","year":"2020","unstructured":"Guttman-Yassky E, Tha\u00e7i D, Pangan AL, et al.. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020, 145:877-84. 10.1016\/j.jaci.2019.11.025","journal-title":"J Allergy Clin Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20229","article-title":"Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis","volume":"38","author":"Silverberg JI","year":"2024","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al.. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024, 38:2139-48. 10.1111\/jdv.20229","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_133_2025","article-title":"Upadacitinib in dermatology: a systematic review of mechanism, current applications, efficacy, safety, and emerging evidence","volume":"92","author":"Dogra S","year":"2026","unstructured":"Dogra S, Prarthana T, Sudharani G, Chhabra S. Upadacitinib in dermatology: a systematic review of mechanism, current applications, efficacy, safety, and emerging evidence. Indian J Dermatol Venereol Leprol. 2026, 92:68-76. 10.25259\/IJDVL_133_2025","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000895","article-title":"The Eczema Area and Severity Index\u2014a practical guide","volume":"33","author":"Hanifin JM","year":"2022","unstructured":"Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The Eczema Area and Severity Index\u2014a practical guide. Dermatitis. 2022, 33:187-92. 10.1097\/DER.0000000000000895","journal-title":"Dermatitis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt A","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, et al.. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021, 157:1047-55. 10.1001\/jamadermatol.2021.3023","journal-title":"JAMA Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials","volume":"158","author":"Simpson EL","year":"2022","unstructured":"Simpson EL, Papp KA, Blauvelt A, et al.. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol. 2022, 158:404-13. 10.1001\/jamadermatol.2022.0029","journal-title":"JAMA Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70172","article-title":"Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6\u2009years","volume":"40","author":"Bunick CG","year":"2026","unstructured":"Bunick CG, Irvine AD, Silverberg JI, et al.. Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6\u2009years. J Eur Acad Dermatol Venereol. 2026, 40:856-66. 10.1111\/jdv.70172","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1246","article-title":"Assessment of pruritus intensity: prospective study on validity and reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 patients with chronic pruritus","volume":"92","author":"Phan NQ","year":"2012","unstructured":"Phan NQ, Blome C, Fritz F, et al.. Assessment of pruritus intensity: prospective study on validity and reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012, 92:502-7. 10.2340\/00015555-1246","journal-title":"Acta Derm Venereol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay AY","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994, 19:210-6. 10.1111\/j.1365-2230.1994.tb01167.x","journal-title":"Clin Exp Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/all.16009","article-title":"Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs","volume":"79","author":"M\u00fcller S","year":"2024","unstructured":"M\u00fcller S, Maintz L, Bieber T. Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs. Allergy. 2024, 79:1501-15. 10.1111\/all.16009","journal-title":"Allergy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.70228","article-title":"Upadacitinib leads in efficacy: a Bayesian network meta-analysis of four JAK inhibitors in moderate-to-severe atopic dermatitis","volume":"65","author":"Babul A","year":"2026","unstructured":"Babul A, Mehta D, Soliman Y, Hussain M, Babul N. Upadacitinib leads in efficacy: a Bayesian network meta-analysis of four JAK inhibitors in moderate-to-severe atopic dermatitis. Int J Dermatol. 2026, 65:1395-409. 10.1111\/ijd.70228","journal-title":"Int J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-01003-0","article-title":"Switching from dupilumab to upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis after inadequate response to dupilumab: efficacy and safety results from period 2 of phase 3b\/4 study (LEVEL UP)","volume":"27","author":"Bunick CG","year":"2026","unstructured":"Bunick CG, Magnolo N, Moore A, et al.. Switching from dupilumab to upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis after inadequate response to dupilumab: efficacy and safety results from period 2 of phase 3b\/4 study (LEVEL UP). Am J Clin Dermatol. 2026, 27:391-9. 10.1007\/s40257-025-01003-0","journal-title":"Am J Clin Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae404","article-title":"Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb\/IV study (Level Up)","volume":"192","author":"Silverberg JI","year":"2024","unstructured":"Silverberg JI, Bunick CG, Hong HC, et al.. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb\/IV study (Level Up). Br J Dermatol. 2024, 192:36-45. 10.1093\/bjd\/ljae404","journal-title":"Br J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.5243","article-title":"Effectiveness of upadacitinib in patients with atopic dermatitis including those with inadequate response to dupilumab and\/or baricitinib: results from the BioDay Registry","volume":"103","author":"Boesjes CM","year":"2023","unstructured":"Boesjes CM, Van der Gang LF, Zuithoff NP, et al.. Effectiveness of upadacitinib in patients with atopic dermatitis including those with inadequate response to dupilumab and\/or baricitinib: results from the BioDay Registry. Acta Derm Venereol. 2023, 103:adv00872. 10.2340\/actadv.v103.5243","journal-title":"Acta Derm Venereol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2192","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update","volume":"160","author":"Drucker AM","year":"2024","unstructured":"Drucker AM, Lam M, Prieto-Merino D, et al.. Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update. JAMA Dermatol. 2024, 160:936-44. 10.1001\/jamadermatol.2024.2192","journal-title":"JAMA Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.64488","article-title":"Efficacy and safety of upadacitinib in moderate-to-severe atopic dermatitis: a meta-analysis","volume":"16","author":"Meher BR","year":"2024","unstructured":"Meher BR, Mishra A, Behera B, Ponnusamy S. Efficacy and safety of upadacitinib in moderate-to-severe atopic dermatitis: a meta-analysis. Cureus. 2024, 16:e64488. 10.7759\/cureus.64488","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/535692-clinical-response-to-upadacitinib-in-treatment-experienced-patients-with-atopic-dermatitis-a-case-series-from-latin-america","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:58:32Z","timestamp":1792418312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/535692-clinical-response-to-upadacitinib-in-treatment-experienced-patients-with-atopic-dermatitis-a-case-series-from-latin-america"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.118166","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,19]]}}}